MGNX analyst estimates

MacroGenics (MGNX) analyst ratings, the average price target and its range, and every firm's latest call.

MGNX analyst ratings and price targets

DateFirmCallTarget
Apr 20, 2026BarclaysMacroGenics price target raised to $6 from $4 at Barclays$6.00
May 14, 2025BarclaysMacroGenics price target lowered to $3 from $8 at Barclays$3.00
Mar 25, 2025H.C. WainwrightMacroGenics price target lowered to $2 from $4 at H.C. Wainwright$2.00
Aug 7, 2024Stifel NicolausMacroGenics (MGNX) PT Lowered to $6 at Stifel$6.00
Jul 31, 2024B.Riley FinancialB.Riley Downgrades MacroGenics (MGNX) to Neutral$5.00
Jul 31, 2024JMP SecuritiesMacroGenics price target lowered to $8 from $16 at JMP Securities$8.00
Jul 29, 2024BarclaysMacroGenics price target lowered to $9 from $14 at Barclays$9.00
May 23, 2024BTIGMacroGenics price target lowered to $9 from $24 at BTIG$9.00
May 13, 2024H.C. WainwrightMacroGenics (MGNX) PT Lowered to $4 at H.C. Wainwright$4.00
May 10, 2024BMO CapitalMacroGenics downgraded to Market Perform from Outperform at BMO Capital$8.00
May 10, 2024BarclaysMacroGenics price target lowered to $14 from $25 at Barclays$14.00
Apr 4, 2024Stifel NicolausStifel on MacroGenics (MGNX): 'incrementally more positive', 'We remain buyers into the next “by May 31” clinical update'$29.00
Nov 22, 2022GuggenheimGuggenheim Upgrades MacroGenics (MGNX) to Buy$12.00
Jul 11, 2022BTIGMacroGenics price target lowered to $6 at BTIG$6.00
Jun 16, 2021WedbushMacroGenics (MGNX) PT Lowered to $32 at Wedbush, Following Clinical Business Update$32.00